EBV-negative aggressive B-cell lymphomas of donor origin after allogeneic hematopoietic stem cell transplantation: a report of three cases

References

• Swerdlow SH, Weber SA, Chadburn A, et al. Post transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, et al., editors. WHO classification of tumours of hematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. p. 220–226.
   Google Scholar
• Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113:4992–5001.
   PubMed Web of Science ®Google Scholar
• Petit B, Le Meur Y, Jaccard A, et al. Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation. Transplantation. 2002;73:265–271.
   PubMed Web of Science ®Google Scholar
• Sala Torra O, Loeb KR. Donor cell-derived leukemia and myelodysplastic neoplasm: unique forms of leukemia. Am J Clin Pathol. 2011;135:501–504.
   PubMed Web of Science ®Google Scholar
• Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol. 1998;16:2052–2059.
   PubMed Web of Science ®Google Scholar
• Knight JS, Tsodikov A, Cibrik DM, et al. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol. 2009;27:3354–3362.
   PubMed Web of Science ®Google Scholar
• Perry AM, Aoun P, Coulter DW, et al. Early onset, EBV(−) PTLD in pediatric liver-small bowel transplantation recipients: a spectrum of plasma cell neoplasms with favorable prognosis. Blood. 2013;121:1377–1383.
   PubMed Web of Science ®Google Scholar
• Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol. 2000;24:375–385.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Habermann TM, Macon WR, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation. 2005;79:244–247.
   PubMed Web of Science ®Google Scholar
• Trimble MS, Waye JS, Walker IR, et al. B-cell lymphoma of recipient origin 9 years after allogeneic bone marrow transplantation for T-cell acute lymphoblastic leukaemia. Br J Haematol. 1993;85:99–102.
   PubMed Web of Science ®Google Scholar
• Drobinskaya I, Gabbert HE, Moeslein G, et al. A new method for optimizing multiplex DNA microsatellite analysis in low quality archival specimens. Anticancer Res. 2005;25:3251–3258.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–2317.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000;14:1307–1325.
   PubMed Web of Science ®Google Scholar
• Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis. 2001;3:60–69.
   PubMedGoogle Scholar
• Chen DB, Song QJ, Chen YX, et al. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2013;97:117–124.
   PubMed Web of Science ®Google Scholar
• Bohn OL, Whitten J, Spitzer B, et al. Posttransplant lymphoproliferative disorder complicating hematopoietic stem cell transplantation in a patient with dyskeratosis congenita. Int J Surg Pathol. 2013;21:520–525.
   PubMed Web of Science ®Google Scholar
• Johnson LR, Nalesnik MA, Swerdlow SH. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders. A histogenetic study. Am J Surg Pathol. 2006;30:1604–1612.
   PubMed Web of Science ®Google Scholar
• Morscio J, Dierickx D, Ferreiro JF, et al. Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant. 2013;13:1305–1316.
   PubMed Web of Science ®Google Scholar
• Quinlan SC, Pfeiffer RM, Morton LM, et al. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol. 2011;86:206–209.
   PubMed Web of Science ®Google Scholar
• Bailey N, Betz B, Roulston D, et al. Aggressive genetic “double-hit” B-cell lymphoma following renal transplantation: case report. J Hematopathol. 2013;6:49–42.
   Web of Science ®Google Scholar
• Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413–1420.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Lorsbach RB, Fend F, et al. Plasmablastic lymphoma and related disorders. Am J Clin Pathol. 2011;136:183–194.
   PubMed Web of Science ®Google Scholar
• Morscio J, Dierickx D, Nijs J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol. 2014;38:875–886.
   PubMed Web of Science ®Google Scholar
• Zimmermann H, Oschlies I, Fink S, et al. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry. Transplantation. 2012;93:543–550.
   PubMed Web of Science ®Google Scholar
• Buell JF, Gross TG, Hanaway MJ, et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc. 2005;37:954–955.
   PubMed Web of Science ®Google Scholar
• Cavaliere R, Petroni G, Lopes MB, et al. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 2010;116:863–870.
   PubMed Web of Science ®Google Scholar
• Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol. 2001;19:772–778.
   PubMed Web of Science ®Google Scholar
• Kinch A, Baecklund E, Backlin C, et al. A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncol. 2014;53:669–679.
   PubMed Web of Science ®Google Scholar
• Snyder MJ, Stenzel TT, Buckley PJ, et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol. 2004;28:794–800.
   PubMed Web of Science ®Google Scholar
• Christian B, Zhao W, Hamadani M, et al. Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. J Clin Oncol. 2010;28:e629–e632.
   PubMed Web of Science ®Google Scholar
• Weigert O, Kopp N, Lane AA, et al. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2012;2:47–55.
   PubMed Web of Science ®Google Scholar